Core Viewpoint - The announcement by Fuhong Hanlin (02696) indicates that its drug, Fuzhuoning® (Acalabrutinib), has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) under Category B, specifically for use in HR-positive, HER2-negative recurrent or metastatic breast cancer patients who have progressed after endocrine therapy [1] Group 1 - Fuzhuoning® is an innovative CDK4/6 small molecule inhibitor licensed by the company [1] - The drug was approved for marketing in China in May 2025, with its first indication being in combination with Fulvestrant for HR-positive, HER2-negative recurrent or metastatic breast cancer patients who have progressed after endocrine therapy [1] - In September 2025, Fuzhuoning® received an additional indication for use in HR-positive, HER2-negative locally advanced or metastatic breast cancer adult patients, in combination with aromatase inhibitors as initial endocrine therapy [1] Group 2 - The new National Medical Insurance Drug List will officially take effect on January 1, 2026 [1]

Core Viewpoint - The announcement by Fuhong Hanlin (02696) regarding the inclusion of Fuzhuoning (Apatinib) in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) is a significant development for the company and the treatment of specific breast cancer patients [1] Group 1 - Fuzhuoning has been included in the Class B category of the National Medical Insurance Drug List for 2025, specifically for use in HR-positive, HER2-negative recurrent or metastatic breast cancer patients who have progressed after endocrine therapy [1] - The new National Medical Insurance Drug List will be officially implemented on January 1, 2026 [1] - Fuzhuoning is an innovative CDK4/6 small molecule inhibitor that was approved for marketing in China in May 2025 [1] Group 2 - The initial approved indication for Fuzhuoning is in combination with Fulvestrant for HR-positive, HER2-negative recurrent or metastatic breast cancer patients who have previously received endocrine therapy [1] - In September 2025, Fuzhuoning received an additional indication for use in HR-positive, HER2-negative locally advanced or metastatic breast cancer adult patients, in combination with aromatase inhibitors as initial endocrine therapy [1]

本次复妥宁获纳入国家医保目录，体现了国家医疗保障局对其临床价值、患者获益、创新程度等方面的 认可，提升了HR阳性、HER2阴性乳腺癌患者可及性，亦有利于复妥宁的市场推广和销售布局。 复妥宁系公司许可引进的创新型CDK4/6小分子抑制剂。2025年5月，于中国境内获批上市，首次获批适 应症为联合氟维司群用于既往接受内分泌治疗后出现疾病进展的激素受体(HR)阳性、人表皮生长因子 受体2(HER2)阴性的复发或转移性成年乳腺癌患者；2025年9月，复妥宁®于中国境内新增获批一项适应 症，用于激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性局部晚期或转移性乳腺癌成人患者：与 芳香化酶抑制剂联合使用作为初始内分泌治疗。 格隆汇12月7日丨复宏汉霖(02696.HK)公告，近日，复妥宁(枸橼酸伏维西利胶囊)获纳入《国家基本医 疗保险、生育保险和工伤保险药品目录(2025年)》("国家医保药品目录")乙类范围，获纳入的适应症为 联合氟维司群用于既往接受内分泌治疗后出现疾病进展的激素受体(HR)阳性、人表皮生长因子受体 2(HER2)阴性的复发或转移性成年乳腺癌患者。新版国家医保药品目录将于2026年1月1日起正式 ...

复妥宁®系公司许可引进的创新型CDK4/6小分子抑制剂。2025年5月，于中国境内获批上市，首次获批 适应症为联合氟维司群用于既往接受内分泌治疗后出现疾病进展的激素受体(HR)阳性、人表皮生长因 子受体2(HER2)阴性的复发或转移性成年乳腺癌患者;2025年9月，复妥宁®于中国境内新增获批一项适 应症，用于激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性局部晚期或转移性乳腺癌成人患者： 与芳香化酶抑制剂联合使用作为初始内分泌治疗。 智通财经APP讯，复宏汉霖(02696)发布公告，近日，复妥宁®(枸橼酸伏维西利胶囊)获纳入《国家基本 医疗保险、生育保险和工伤保险药品目录(2025年 )》乙类范围，获纳入的适应症为联合氟维司群用于既 往接受内分泌治疗后出现疾病进展的激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的复发或转 移性成年乳腺癌患者。新版国家医保药品目录将于2026年1月1日起正式实施。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 自願公告 複妥寧® （枸櫞酸伏維西利膠囊）獲納入國家醫保藥品目錄 A. 緒言 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）自願作出，以告知 本公司股東及潛在投資者本公司最新業務更新。 B. 關於複妥寧® 複妥寧®係本公司許可引進的創新型CDK4/6小分子抑制劑。2025年5月，於 中國境內獲批上市，首次獲批適應症為聯合氟維司群用於既往接受內分泌治 療後出現疾病進展的激素受體(HR)陽性、人表皮生長因子受體2(HER2)陰性 的複發或轉移性成年乳腺癌患者；2025年9月，複妥寧®於中國境內新增獲批 一項適應症，用於激素受體(HR)陽性、人表皮生長因子受體2(HER2)陰性局 部晚期或轉移性乳腺癌成人患者：與芳香化酶抑制劑聯合使用作為初始 ...

Core Insights - China National Pharmaceutical Group (Sinopharm) has renewed its distribution partnership with Fuhong Hanlin, which will last from January 1, 2026, to December 31, 2028, focusing on the commercialization of innovative biopharmaceutical products [1][10]. Group 1: Partnership with Fuhong Hanlin - Fuhong Hanlin, a biopharmaceutical company, has a strong product matrix and approximately 50 molecules in development, ensuring a stable supply of new products for Sinopharm [3][5]. - The sales cap for the renewed partnership is set at 12.224 billion RMB over three years, with expected sales growth driven by new product launches and existing product demand [5][17]. - Specific sales growth expectations include a 0.8% increase in 2027 and a 14.2% increase in 2028, attributed to new indications and innovative products [5][17]. Group 2: Strategic Collaborations - Sinopharm is accelerating collaborations with upstream industrial partners, including a recent strategic partnership with Pierre Fabre, a French pharmaceutical company [5][19]. - The company is also engaging with other multinational pharmaceutical giants like AstraZeneca and Bristol-Myers Squibb to explore strategic synergies and innovative business models [19][20]. - Domestic collaborations are also progressing, with Sinopharm partnering with Tianjin Pharmaceutical Group to enhance channel integration and product offerings [21][22]. Group 3: Retail and Operational Performance - Sinopharm's retail arm, Guoda Pharmacy, is transforming its procurement system and has seen a 11.3% year-on-year sales growth in core products from industrial partners in the first half of 2025 [23]. - The company reported a revenue of 431.5 billion RMB in the first three quarters of 2025, with a reduced year-on-year decline of 2.47% [23]. - Recent leadership changes, including the resignation of Chairman Zhao Bingxiang, signal a potential shift in strategic direction for Sinopharm [24].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海復宏漢霖生物技術股份有限公司 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02696 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 163,428,541 | RMB | | 1 RMB | | 163,428,541 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 163,428,541 | RMB | | 1 RMB | | 163,428,541 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 ...

Core Viewpoint - The collaboration between Fuhong Hanlin and Aohong Pharmaceutical aims to accelerate the commercialization process of the innovative small molecule CDK4/6 inhibitor, Fovetizumab (brand name: Fuzhening) [1] Group 1: Company Collaboration - Fuhong Hanlin has announced a partnership with Aohong Pharmaceutical to expedite the commercialization of Fuzhening [1] - Fuzhening has received approval in China for use in patients with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have progressed after initial endocrine therapy [1] - Aohong Pharmaceutical developed Fuzhening, while Fuhong Hanlin holds exclusive commercialization rights in China [1]

Group 1 - The core point of the article is the collaboration between Fuhong Hanlin and Aohong Pharmaceutical to accelerate the commercialization of the innovative small molecule CDK4/6 inhibitor, Fovetizumab (brand name: Fuzhuoning) [1] - Fuzhuoning has been approved in China for use in patients with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have either received initial endocrine therapy or have progressed after prior endocrine treatment [1] - Aohong Pharmaceutical developed Fuzhuoning, while Fuhong Hanlin holds exclusive commercialization rights in China [1]

Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 將於2025年12月31日舉行的2025年第四次臨時股東會 （或其任何續會）適用的代表委任表格 | 本代表委任表格所代表的 | 非上市股份 | | --- | --- | | （附註1） 股份數目 | H股 | 本人/吾等 （附註2） 地址為 收集個人資料聲明 閣下是自願提供 閣下及 閣下委任代表的姓名及地址，以用於處理就臨時股東會有關 閣下委任代表的任命及投票指示（「該等用途」）。吾等可能向為本公司提供行政、電 腦及其他服務的代理人、承辦商或第三者服務供應商，以及其他獲法例授權而要求取得有關資料的人士或其他與上述所列出的該等用途有關以及需要接收有關資料之人士提 供 閣下及 閣下委任代表的姓名及地址。 閣下所提供 閣下及 閣下委任代表的姓名及地址將就履行上述該等用途所需的時間保留。有關存取及/或更正相關個人資料的要 求可按照《個人資料（私隱）條例》提出，而有關要求均須以書面郵寄至本公司之香港主要營業地點，地址為香港夏慤道16號遠東金融中心17樓。 ...